Yahoo Web Search

Sign In

Search results

  1. www.hospital.kisarazu.chiba.jpHOME - 君津中央病院公式サイト

    君津中央病院企業団運営委員会会議録の公開について (R6.04.23) 令和5年度企業団議会会議録を掲載しました（R6.04.19）. 紹介患者さんを優先的にお受けしております. 当院は、君津保健医療圏内で高度急性期医療を担う唯一の医療機関として、より病状の重い ...

  2. www.linkedin.com › company › kimitsu-chuo-hospitalKimitsu Chuo Hospital - LinkedIn

    Kimitsu Chuo Hospital | 69 followers on LinkedIn. Kimitsu Chuo Hospital is located at Kisarazu, Chiba, Japan.

  3. www.hospital.kisarazu.chiba.jp › the-news › the-news病院情報の公表について（R6.10.01） - 君津中央病院公式サイト

    病院情報の公表について（R6.10.01） - 君津中央病院公式サイト. 君津中央病院公式サイト. 〒292-8535千葉県木更津市桜井1010. TEL：0438-36-1071㈹. 現在地: ホーム お知らせ 当院を利用される方へお知らせ 病院情報の公表について（R6.10.01）.

  4. aphn.org › services › kimitsu-central-hospitalKimitsu Central Hospital - APHN

    Kimitsu Central Hospital - APHN. Address: 1010 Sakurai, Kisarazu-chi, Chiba 292-8535, Japan Phone:Email:Website: http://www.hospital.kisarazu.chiba.jp/ Services Provided: Inpatient Service (Dedicated beds for palliative care) Outpatient Clinic. Palliative Care Consultancy.

  5. pubmed.ncbi.nlm.nih.gov › 32542431Safety and Efficacy of Ranibizumab and Luseogliflozin Combination...

    Affiliations. 1 Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, 1010 Sakurai, Kisarazu, Chiba, 292-8535, Japan. ishibashi-cib@umin.net.

  6. onlinelibrary.wiley.com › doi › 10Risk factors for unsuccessful atropine therapy in hypertrophic...

    Sep 14, 2019 · I.v. atropine (IA) for infantile hypertrophic pyloric stenosis (IHPS) is a good alternative to pyloromyotomy but has not been broadly accepted. The lower success rate is one of the greatest disadvantages of IA. We investigated the risk factors for unsuccessful results following IA for IHPS.

  7. pubmed.ncbi.nlm.nih.gov › 37604846Treatment strategy changes for inflammatory bowel diseases in...

    Aug 21, 2023 · This study aimed to reveal the changes in patient characteristics and the therapeutic strategies of IBD before and after the implementation of biologics in Japan, where the unique health insurance system allows patients with IBD and physicians to select drugs with minimum patient expenses.